- Home
- JZXN vs NRXS Comparison
JZXN vs NRXS Comparison
Compare JZXN & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- NRXS
- Stock Information
- Founded
- JZXN 2017
- NRXS 2011
- Country
- JZXN China
- NRXS United States
- Employees
- JZXN N/A
- NRXS N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- NRXS
- Sector
- JZXN Consumer Discretionary
- NRXS
- Exchange
- JZXN Nasdaq
- NRXS Nasdaq
- Market Cap
- JZXN 14.6M
- NRXS 17.3M
- IPO Year
- JZXN 2021
- NRXS 2023
- Fundamental
- Price
- JZXN $1.57
- NRXS $2.85
- Analyst Decision
- JZXN
- NRXS
- Analyst Count
- JZXN 0
- NRXS 0
- Target Price
- JZXN N/A
- NRXS N/A
- AVG Volume (30 Days)
- JZXN 160.2K
- NRXS 30.7K
- Earning Date
- JZXN 09-09-2024
- NRXS 11-12-2024
- Dividend Yield
- JZXN N/A
- NRXS N/A
- EPS Growth
- JZXN N/A
- NRXS N/A
- EPS
- JZXN N/A
- NRXS N/A
- Revenue
- JZXN $7,597,423.00
- NRXS $2,456,219.00
- Revenue This Year
- JZXN N/A
- NRXS $383.16
- Revenue Next Year
- JZXN N/A
- NRXS N/A
- P/E Ratio
- JZXN N/A
- NRXS N/A
- Revenue Growth
- JZXN 81.94
- NRXS N/A
- 52 Week Low
- JZXN $1.00
- NRXS $2.00
- 52 Week High
- JZXN $67.60
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- JZXN 53.86
- NRXS 61.76
- Support Level
- JZXN $1.41
- NRXS $2.48
- Resistance Level
- JZXN $1.63
- NRXS $2.83
- Average True Range (ATR)
- JZXN 0.16
- NRXS 0.26
- MACD
- JZXN 0.01
- NRXS 0.05
- Stochastic Oscillator
- JZXN 54.00
- NRXS 72.86
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).